Slingshot members are tracking this corporate initiative:
Ocular Therapeutics (OCUL) and Regeneron (REGN) Agree to Develop a Sustained-Release Formulation of Aflibercept for Wet Age-Related Macular Degeneration (Wet AMD)
Slingshot Insights Explained
Strategic Initiative Date
Announcement Date: Oct 13, 2016 Projected Implementation: Q4, 2016 Relevance Tracked Until: Q4, 2017
Don’t see a project related to the strategic initiative you care about?
Related Keywords Strategic Initiative, Aflibercept, Wet Age-related Macular Degeneration, Wet Amd, Sustained-release Formulation, Product Development